FDA authorizes Vitestro's Aletta robot for autonomous blood draws

Why it matters

Vitestro has secured the first U.S. authorization for a standalone robotic blood-draw system, creating a regulatory path for automating routine phlebotomy. Commercial adoption will turn on supervision costs, reliability and workflow integration.

Toon Overbeeke and Brian Joseph spent nine years turning two difficult family blood-draw experiences into Aletta, and on August 19th, 2026, the FDA authorized their robot to perform the procedure without hands-on operator intervention.

The decision makes Aletta the first standalone robotic blood-draw device authorized in the United States, according to the FDA. The De Novo decision establishes a regulatory category for a device that combines imaging, robotics and automated sample handling to complete one of medicine's most routine invasive procedures.

For Overbeeke, Vitestro's CEO, and Joseph, its vice president of product vision, the original problem was personal. Overbeeke had watched a friend's father endure repeated needle punctures during chemotherapy. Joseph encountered long waits and logistical errors when one of his children needed recurring blood tests. They founded Utrecht-based Vitestro in 2017 around the thesis that a standardized machine could reduce the variability built into manual blood collection.

Joseph had already built and run open-source software developer Zarafa, which Amazon acquired in 2013. Overbeeke brought an engineering and consulting background. Their harder task at Vitestro was building a machine that could find a vein, distinguish it from an artery, insert a needle and manage multiple collection tubes in a clinical setting where small errors can compromise a sample or injure a patient.

A robot runs the draw, with a phlebotomist nearby

Aletta guides the patient into position, uses near-infrared imaging and Doppler ultrasound to select a vein, applies a tourniquet and disinfects the skin. It then inserts and disposes of the needle, changes and inverts collection tubes, withdraws the needle and applies a bandage.

The machine stops before inserting a needle if it cannot identify an appropriate vein. During a draw, onboard sensors can pause the procedure when they detect an unsafe condition. Excessive patient movement triggers the needle to detach automatically.

That autonomy still comes with a staffing requirement. A trained phlebotomy supervisor initiates each session, remains available during the procedure, checks that tubes were collected in the correct order and verifies that they contain enough blood. A trained professional also cleans Aletta between patients. The FDA says one phlebotomist can supervise as many as three devices simultaneously.

The ratio is central to Vitestro's business case. The 2024 American Society for Clinical Pathology vacancy survey found a 9.4% vacancy rate in phlebotomy departments at U.S. medical laboratories, including 9.9% for staff positions. Respondents described night and overtime shifts as difficult to fill and double shifts as very difficult.

Aletta is designed to move routine outpatient draws through a standardized process while skilled staff handle patients who need closer attention. Whether that arrangement produces meaningful savings will depend on device pricing, utilization and the amount of intervention required during everyday operation. The published clinical research assessed performance and safety rather than labor costs or throughput economics.

The headline success rate has a denominator

A peer-reviewed multicenter study published in Clinical Chemistry reported a 94.5% first-stick success rate across 1,633 patients. The result applies to patients for whom Aletta had already identified a suitable vein.

The system screened 1,743 participants and did not identify a suitable vein in 110, or 6%, who were then referred for manual phlebotomy and excluded from the first-stick calculation. Among the enrolled patients, first-stick success was 92.7% for the 411 who reported difficult venous access and 93.4% for the 695 patients aged 65 or older.

The study reported mild adverse events in 0.6% of Aletta procedures and no serious adverse events. The overall hemolysis rate among samples with available measurements was 0.3%. Hemolysis varied specifically by trial site, reaching 5.2% at site 1 and 0% at sites 2 and 3. Hemolysis can make a blood sample unusable or distort test results, making repeat draws a costly part of the workflow Vitestro is trying to standardize.

The evidence carries an important disclosure. Vitestro funded the study, and Vitestro employees or equity holders were among its authors. The paper says Vitestro participated in the study design, patient selection, data interpretation and manuscript preparation. Its results supported the regulatory case, while broader independent use will determine how reliably the machine performs outside closely managed trials.

Authorization comes before the U.S. rollout

Vitestro received European CE marking in August 2024 and says Aletta is being introduced in clinical and pre-commercial settings in Europe. The U.S. authorization covers adult patients in outpatient settings, but Vitestro says it plans another U.S. multicenter clinical trial before commercial availability. The timing of that trial and a U.S. launch has not been set out in Vitestro's public announcement.

That leaves manufacturing, installation, training and hospital procurement between the FDA decision and a machine drawing blood at scale in American laboratories. Vitestro said in its August 20th authorization announcement that it would build manufacturing capacity and commercial infrastructure while planning a phased rollout.

Vitestro financed that work in March with a $70 million Series B. The investor group included Labcorp Venture Fund, Mayo Clinic, Sutter Health, InterVest, MGFO, PGGM, Puma Venture Capital and ROM Utrecht, alongside Invest-NL, EIC Fund, Fred Moll, NYBC Ventures and Sonder Capital.

The healthcare investors matter as much as the size of the check. Laboratory operators and health systems can help Vitestro test Aletta against the realities of high-volume outpatient care, including scheduling, sample transport, cleaning cycles and integration with laboratory systems. Sonder Capital co-founder Fred Moll, who helped build Intuitive Surgical and Auris Health, also gives Vitestro an investor with experience taking medical robots from engineering projects into regulated clinical products.

Other developers, including California-based Veebot and VascuLogic, have worked on image-guided robotic needle insertion. Aletta's advantage is now regulatory: Vitestro crossed the FDA threshold for a standalone system that carries out the full blood-draw sequence. Its next test is operational. Hospitals will judge the robot on how many draws it can complete, which patients still need a human and whether three machines under one supervisor work as cleanly on a busy morning as the staffing model suggests.